After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | The company doubled sales of its Biogen-partnered Alzheimer's disease treatment during its 2025 fiscal year.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.
Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift…
